Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma

医学 哮喘 屋尘螨 过敏 恶化 安慰剂 福莫特罗 不利影响 随机对照试验 沙丁胺醇 变应原免疫治疗 随机化 过敏原 狭缝 内科学 免疫学 布地奈德 替代医学 病理 生物 遗传学
作者
Johann Christian Virchow Jr.,Vibeke Backer,Piotr Kuna,Luis Manuel Prieto,Hendrik Nolte,Hanne H. Villesen,Christian Ljørring,Bente Riis,Frederic de BLAY
出处
期刊:JAMA [American Medical Association]
卷期号:315 (16): 1715-1715 被引量:439
标识
DOI:10.1001/jama.2016.3964
摘要

IMPORTANCE: The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy-related asthma. OBJECTIVES: To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period. DESIGN, SETTINGS, AND PARTICIPANTS: Double-blind, randomized, placebo-controlled trial conducted between August 2011 and April 2013 in 109 European trial sites. The trial included 834 adults with HDM allergy-related asthma not well controlled by ICS or combination products, and with HDM allergy-related rhinitis. Key exclusion criteria were FEV1 less than 70% of predicted value or hospitalization due to asthma within 3 months before randomization. Efficacy was assessed during the last 6 months of the trial when ICS was reduced by 50% for 3 months and then completely withdrawn for 3 months. INTERVENTIONS: 1:1:1 randomization to once-daily treatment with placebo (n = 277) or HDM SLIT tablet (dosage groups: 6 SQ-HDM [n = 275] or 12 SQ-HDM [n = 282]) in addition to ICS and the short-acting β2-agonist salbutamol. MAIN OUTCOMES AND MEASURES: Primary outcome was time to first moderate or severe asthma exacerbation during the ICS reduction period. Secondary outcomes were deterioration in asthma symptoms, change in allergen-specific immunoglobulin G4 (IgG4), change in asthma control or asthma quality-of-life questionnaires, and adverse events. RESULTS: Among 834 randomized patients (mean age, 33 years [range, 17-83]; women, 48%), 693 completed the study. The 6 SQ-HDM and 12 SQ-HDM doses both significantly reduced the risk of a moderate or severe asthma exacerbation compared with placebo (hazard ratio [HR]: 0.72 [95% CI, 0.52-0.99] for the 6 SQ-HDM group, P = .045, and 0.69 [95% CI, 0.50-0.96] for the 12 SQ-HDM group, P = .03). The absolute risk differences based on the observed data (full analysis set) in the active groups vs the placebo group were 0.09 (95% CI, 0.01-0.15) for the 6 SQ-HDM group and 0.10 (95% CI, 0.02-0.16) for the 12 SQ-HDM group. There was no significant difference between the 2 active groups. Compared with placebo, there was a reduced risk of an exacerbation with deterioration in asthma symptoms (HR, 0.72 [95% CI, 0.49-1.02] for the 6 SQ-HDM group, P = .11, and 0.64 [95% CI, 0.42-0.96] for the 12 SQ-HDM group, P = .03) and a significant increase in allergen-specific IgG4. However, there was no significant difference for change in asthma control questionnaire or asthma quality-of-life questionnaire for either dose. There were no reports of severe systemic allergic reactions. The most frequent adverse events were mild to moderate oral pruritus (13% for the 6 SQ-HDM group, 20% for the 12 SQ-HDM group, and 3% for the placebo group), mouth edema, and throat irritation. CONCLUSIONS AND RELEVANCE: Among adults with HDM allergy-related asthma not well controlled by ICS, the addition of HDM SLIT to maintenance medications improved time to first moderate or severe asthma exacerbation during ICS reduction, with an estimated absolute reduction at 6 months of 9 to 10 percentage points; the reduction was primarily due to an effect on moderate exacerbations. Treatment-related adverse events were common at both active doses. Further studies are needed to assess long-term efficacy and safety. TRIAL REGISTRATION: clinicaltrialsregister.eu Identifier: 2010-018621-19.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
谦让馒头完成签到 ,获得积分10
刚刚
如懿发布了新的文献求助10
1秒前
笙笙发布了新的文献求助10
1秒前
来文献完成签到 ,获得积分10
2秒前
ccq的应助被科研通管家采纳,获得10
3秒前
快乐是无敌完成签到,获得积分20
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
null的应助被科研通管家采纳,获得10
3秒前
华仔的应助被科研通管家采纳,获得10
3秒前
在水一方的应助被科研通管家采纳,获得10
3秒前
3秒前
我是老大的应助被科研通管家采纳,获得10
3秒前
yiyi1发布了新的文献求助10
3秒前
上官若男的应助被科研通管家采纳,获得30
3秒前
3秒前
大模型的应助被科研通管家采纳,获得10
4秒前
勤奋柜子的应助被li采纳,获得20
4秒前
小马甲的应助被科研通管家采纳,获得10
4秒前
小马甲的应助被科研通管家采纳,获得10
4秒前
所所的应助被科研通管家采纳,获得10
4秒前
JamesPei的应助被科研通管家采纳,获得10
4秒前
小蘑菇的应助被科研通管家采纳,获得10
4秒前
发芽的星期天完成签到,获得积分20
4秒前
隐形曼青的应助被科研通管家采纳,获得10
4秒前
华仔的应助被科研通管家采纳,获得10
5秒前
WAKAKA发布了新的文献求助10
5秒前
赘婿的应助被科研通管家采纳,获得10
5秒前
cxyyy发布了新的文献求助10
5秒前
Lucas的应助被科研通管家采纳,获得10
5秒前
5秒前
糖糖完成签到,获得积分10
5秒前
JamesPei的应助被Night_tix9y采纳,获得10
5秒前
6秒前
三分之二发布了新的文献求助10
7秒前
于鱼完成签到,获得积分10
7秒前
nixay621完成签到,获得积分20
8秒前
王宝宝关注了科研通微信公众号
8秒前
JamesPei的应助被糖糖采纳,获得10
9秒前
阿渊完成签到,获得积分10
9秒前
秋风的应助被11采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034